These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
186 related articles for article (PubMed ID: 33495309)
1. Preclinical Evaluation and Phase Ib Study of Prexasertib, a CHK1 Inhibitor, and Samotolisib (LY3023414), a Dual PI3K/mTOR Inhibitor. Hong DS; Moore KN; Bendell JC; Karp DD; Wang JS; Ulahannan SV; Jones S; Wu W; Donoho GP; Ding Y; Capen A; Wang X; Bence Lin A; Patel MR Clin Cancer Res; 2021 Apr; 27(7):1864-1874. PubMed ID: 33495309 [TBL] [Abstract][Full Text] [Related]
2. A phase 1 dose-escalation study of checkpoint kinase 1 (CHK1) inhibitor prexasertib in combination with p38 mitogen-activated protein kinase (p38 MAPK) inhibitor ralimetinib in patients with advanced or metastatic cancer. Bendell JC; Bischoff HG; Hwang J; Reinhardt HC; Zander T; Wang X; Hynes S; Pitou C; Campbell R; Iversen P; Farrington DL; Bell-McGuinn K; Thomas M Invest New Drugs; 2020 Aug; 38(4):1145-1155. PubMed ID: 31707688 [TBL] [Abstract][Full Text] [Related]
3. A phase 1 study of prexasertib (LY2606368), a CHK1/2 inhibitor, in pediatric patients with recurrent or refractory solid tumors, including CNS tumors: A report from the Children's Oncology Group Pediatric Early Phase Clinical Trials Network (ADVL1515). Cash T; Fox E; Liu X; Minard CG; Reid JM; Scheck AC; Weigel BJ; Wetmore C Pediatr Blood Cancer; 2021 Sep; 68(9):e29065. PubMed ID: 33881209 [TBL] [Abstract][Full Text] [Related]
4. A Phase II Single Arm Pilot Study of the CHK1 Inhibitor Prexasertib (LY2606368) in BRCA Wild-Type, Advanced Triple-Negative Breast Cancer. Gatti-Mays ME; Karzai FH; Soltani SN; Zimmer A; Green JE; Lee MJ; Trepel JB; Yuno A; Lipkowitz S; Nair J; McCoy A; Lee JM Oncologist; 2020 Dec; 25(12):1013-e1824. PubMed ID: 32510664 [TBL] [Abstract][Full Text] [Related]
5. Evaluation of Prexasertib, a Checkpoint Kinase 1 Inhibitor, in a Phase Ib Study of Patients with Squamous Cell Carcinoma. Hong DS; Moore K; Patel M; Grant SC; Burris HA; William WN; Jones S; Meric-Bernstam F; Infante J; Golden L; Zhang W; Martinez R; Wijayawardana S; Beckmann R; Lin AB; Eng C; Bendell J Clin Cancer Res; 2018 Jul; 24(14):3263-3272. PubMed ID: 29643063 [No Abstract] [Full Text] [Related]
6. The Checkpoint Kinase 1 Inhibitor Prexasertib Induces Regression of Preclinical Models of Human Neuroblastoma. Lowery CD; VanWye AB; Dowless M; Blosser W; Falcon BL; Stewart J; Stephens J; Beckmann RP; Bence Lin A; Stancato LF Clin Cancer Res; 2017 Aug; 23(15):4354-4363. PubMed ID: 28270495 [No Abstract] [Full Text] [Related]
7. Phase 1 dose-escalation study of a novel oral PI3K/mTOR dual inhibitor, LY3023414, in patients with cancer. Kondo S; Tajimi M; Funai T; Inoue K; Asou H; Ranka VK; Wacheck V; Doi T Invest New Drugs; 2020 Dec; 38(6):1836-1845. PubMed ID: 32578154 [TBL] [Abstract][Full Text] [Related]
8. Broad Spectrum Activity of the Checkpoint Kinase 1 Inhibitor Prexasertib as a Single Agent or Chemopotentiator Across a Range of Preclinical Pediatric Tumor Models. Lowery CD; Dowless M; Renschler M; Blosser W; VanWye AB; Stephens JR; Iversen PW; Lin AB; Beckmann RP; Krytska K; Cole KA; Maris JM; Hawkins DS; Rubin BP; Kurmasheva RT; Houghton PJ; Gorlick R; Kolb EA; Kang MH; Reynolds CP; Erickson SW; Teicher BA; Smith MA; Stancato LF Clin Cancer Res; 2019 Apr; 25(7):2278-2289. PubMed ID: 30563935 [TBL] [Abstract][Full Text] [Related]
9. A First-in-Human Phase 1 Study of LY3023414, an Oral PI3K/mTOR Dual Inhibitor, in Patients with Advanced Cancer. Bendell JC; Varghese AM; Hyman DM; Bauer TM; Pant S; Callies S; Lin J; Martinez R; Wickremsinhe E; Fink A; Wacheck V; Moore KN Clin Cancer Res; 2018 Jul; 24(14):3253-3262. PubMed ID: 29636360 [No Abstract] [Full Text] [Related]
10. The CHK1 Inhibitor Prexasertib Exhibits Monotherapy Activity in High-Grade Serous Ovarian Cancer Models and Sensitizes to PARP Inhibition. Parmar K; Kochupurakkal BS; Lazaro JB; Wang ZC; Palakurthi S; Kirschmeier PT; Yang C; Sambel LA; Färkkilä A; Reznichenko E; Reavis HD; Dunn CE; Zou L; Do KT; Konstantinopoulos PA; Matulonis UA; Liu JF; D'Andrea AD; Shapiro GI Clin Cancer Res; 2019 Oct; 25(20):6127-6140. PubMed ID: 31409614 [TBL] [Abstract][Full Text] [Related]
11. Phase 1 Combination Study of the CHK1 Inhibitor Prexasertib and the PARP Inhibitor Olaparib in High-grade Serous Ovarian Cancer and Other Solid Tumors. Do KT; Kochupurakkal B; Kelland S; de Jonge A; Hedglin J; Powers A; Quinn N; Gannon C; Vuong L; Parmar K; Lazaro JB; D'Andrea AD; Shapiro GI Clin Cancer Res; 2021 Sep; 27(17):4710-4716. PubMed ID: 34131002 [TBL] [Abstract][Full Text] [Related]
12. A Phase 1b Trial of Prexasertib in Combination with Standard-of-Care Agents in Advanced or Metastatic Cancer. Moore KN; Hong DS; Patel MR; Pant S; Ulahannan SV; Jones S; Meric-Bernstam F; Wang JS; Aljumaily R; Hamilton EP; Wittchen ES; Wang X; Lin AB; Bendell JC Target Oncol; 2021 Sep; 16(5):569-589. PubMed ID: 34559360 [TBL] [Abstract][Full Text] [Related]
13. Dose-finding study of the checkpoint kinase 1 inhibitor, prexasertib, in Japanese patients with advanced solid tumors. Iwasa S; Yamamoto N; Shitara K; Tamura K; Matsubara N; Tajimi M; Lin AB; Asou H; Cai Z; Inoue K; Shibasaki Y; Saito K; Takai H; Doi T Cancer Sci; 2018 Oct; 109(10):3216-3223. PubMed ID: 30040168 [TBL] [Abstract][Full Text] [Related]
14. Prexasertib treatment induces homologous recombination deficiency and synergizes with olaparib in triple-negative breast cancer cells. Mani C; Jonnalagadda S; Lingareddy J; Awasthi S; Gmeiner WH; Palle K Breast Cancer Res; 2019 Sep; 21(1):104. PubMed ID: 31492187 [TBL] [Abstract][Full Text] [Related]
15. Phase 1 cohort expansion study of LY3023414, a dual PI3K/mTOR inhibitor, in patients with advanced mesothelioma. Zauderer MG; Alley EW; Bendell J; Capelletto E; Bauer TM; Callies S; Szpurka AM; Kang S; Willard MD; Wacheck V; Varghese AM Invest New Drugs; 2021 Aug; 39(4):1081-1088. PubMed ID: 33660194 [TBL] [Abstract][Full Text] [Related]
16. Phase I study of the checkpoint kinase 1 inhibitor GDC-0575 in combination with gemcitabine in patients with refractory solid tumors. Italiano A; Infante JR; Shapiro GI; Moore KN; LoRusso PM; Hamilton E; Cousin S; Toulmonde M; Postel-Vinay S; Tolaney S; Blackwood EM; Mahrus S; Peale FV; Lu X; Moein A; Epler J; DuPree K; Tagen M; Murray ER; Schutzman JL; Lauchle JO; Hollebecque A; Soria JC Ann Oncol; 2018 May; 29(5):1304-1311. PubMed ID: 29788155 [TBL] [Abstract][Full Text] [Related]
17. Phase Ib/II Study of Enzalutamide with Samotolisib (LY3023414) or Placebo in Patients with Metastatic Castration-Resistant Prostate Cancer. Sweeney CJ; Percent IJ; Babu S; Cultrera JL; Mehlhaff BA; Goodman OB; Morris DS; Schnadig ID; Albany C; Shore ND; Sieber PR; Guba SC; Zhang W; Wacheck V; Donoho GP; Szpurka AM; Callies S; Lin BK; Bendell JC Clin Cancer Res; 2022 Jun; 28(11):2237-2247. PubMed ID: 35363301 [TBL] [Abstract][Full Text] [Related]
18. Prexasertib: an investigational checkpoint kinase inhibitor for the treatment of high-grade serous ovarian cancer. Evangelisti G; Barra F; Moioli M; Sala P; Stigliani S; Gustavino C; Costantini S; Ferrero S Expert Opin Investig Drugs; 2020 Aug; 29(8):779-792. PubMed ID: 32539469 [TBL] [Abstract][Full Text] [Related]
19. Phase 1b study of combined selinexor and eribulin for the treatment of advanced solid tumors and triple-negative breast cancer. Nelson BE; Saleem S; Damodaran S; Somaiah N; Piha-Paul S; Moore JA; Yilmaz B; Ogbonna D; Karp DD; Dumbrava E; Tsimberidou AM; Hong DS; Rodon Ahnert J; Milton DR; Zheng X; Booser DJ; Ibrahim NK; Conley AP; Bhosale P; Rojas Hernandez CM; Tripathy D; Naing A; Meric-Bernstam F Cancer; 2023 Jul; 129(14):2201-2213. PubMed ID: 37016732 [TBL] [Abstract][Full Text] [Related]
20. CNS penetration and pharmacodynamics of the CHK1 inhibitor prexasertib in a mouse Group 3 medulloblastoma model. Campagne O; Davis A; Maharaj AR; Zhong B; Stripay J; Farmer D; Roussel MF; Stewart CF Eur J Pharm Sci; 2020 Jan; 142():105106. PubMed ID: 31669383 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]